

Canada

Population 2017

37 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.11 (0.11–0.11)	0.3 (0.3–0.3)
Mortality (HIV+TB only)	0.025 (0.016–0.035)	0.07 (0.04–0.1)
Incidence (includes HIV+TB)	2 (1.7–2.3)	5.5 (4.7–6.3)
Incidence (HIV+TB only)	0.16 (0.13–0.19)	0.44 (0.36–0.52)
Incidence (MDR/RR-TB)**	0.024 (0.011–0.042)	0.07 (0.03–0.12)

Estimated TB incidence by age and sex (thousands)*, 2017			
	0-14 years	> 14 years	Total
Females	0.069 (0.067–0.071)	0.85 (0.76–0.93)	0.91 (0.82–1)
Males	0.083 (0.081–0.086)	1 (0.9–1.1)	1.1 (0.97–1.2)
Total	0.15 (0.15–0.16)	1.8 (1.6–2.1)	2 (1.7–2.3)

TB case notifications, 2017	
Total cases notified	
Total new and relapse	
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	
- % pulmonary	
- % bacteriologically confirmed among pulmonary	

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2017	
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.07 (0.06–0.08)

TB/HIV care in new and relapse TB patients, 2017		
	Number	(%)
Patients with known HIV-status who are HIV-positive	23	2%
- on antiretroviral therapy		

Drug-resistant TB care, 2017			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			(-)
Estimated % of TB cases with MDR/RR-TB	0.82% (0.33–1.7)	6.3% (1.7–15)	
% notified tested for rifampicin resistance			1 152
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2016		
Previously treated cases, excluding relapse, registered in 2016		
HIV-positive TB cases registered in 2016		
MDR/RR-TB cases started on second-line treatment in 2015		
XDR-TB cases started on second-line treatment in 2015		

TB preventive treatment, 2017	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2018	
National TB budget (US\$ millions)	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence

— Notified (new and relapse)


— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017



■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse

— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB